Article
Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Antimicrobial agents and chemotherapy - 1 Oct 2004
Smith Heather J, Walters Michael, Hisanaga Tamiko, Zhanel George G, Hoban Daryl J
Abstract excerpt
Three fluoroquinolone-susceptible and five fluoroquinolone-resistant (two with ParC Ser79Phe mutations, one with a GyrA Ser81Phe mutation, and two that were efflux positive) Streptococcus pneumoniae isolates were exposed to one, two, four, eight, and sixteen times the MICs of ciprofloxacin, gatif...
Topics
- Anti-Infective Agents
- Antimutagenic Agents
- DNA Gyrase
- DNA Topoisomerase IV
- Drug Resistance, Microbial
- Fluoroquinolones
- Humans
- Mutation
- Pneumococcal Infections
- Streptococcus pneumoniae